Filer Snapshot

Atai Beckley N.V.

CIK 0001840904. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

119

Latest filing

26 Nov 2025

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13D/G stake for CMPS. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13D/G history Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

CMPS

27 Oct 2025 · 6% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Forms 3/4/5

4 filed on 26 Nov 2025 for CIK 0001840904.

View source filing
Listed symbols
ATAI on Nasdaq
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

Forms 3/4/5 positions$41.78M

Reporting-owner positions with enough filing detail to estimate value.

Forms 3/4/5 position value

3/4/5
$41.78M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

CMPS

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

CMPS
How to read these SEC ownership signals
  • Read each filing family separately: 13F portfolios, 13D/G large stakes, and Forms 3/4/5 owner positions answer different SEC disclosure questions.
  • Open the linked research path when you need the filing, CIK, issuer, or CUSIP trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
Prof. J.H. Bavincklaan 7, Amstelveen, 1183
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
Netherlands
Fiscal year end
31 December
Former names on EDGAR
ATAI Life Sciences N.V. (to 05 Nov 2025), ATAI Life Sciences B.V. (to 21 Jun 2021)

Filer intelligence

What SEC filings say about Atai Beckley N.V.

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • 1 recent 13D/G stake row found; top row is CMPS at 6% ownership.
  • Forms 3/4/5 show insider context for CMPS worth $41.78M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes 1 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 2 rows

Officer, director, and 10% owner holdings or transactions.

Open

13D/G large-stake context

CMPS

27 Oct 2025 · Ordinary Shares

6%
Issuer page 13D/G history

Forms 3/4/5 insider context

CMPS

26 Sep 2024 · 10% owner

$41.78M
Issuer page Owner page

IGXT

19 Apr 2024 · 10% owner

Issuer page Owner page

Latest update

What changed recently for Atai Beckley N.V.

New fact period available

Latest financial period: Q3 2025. Open the source-backed page to inspect the fresh filing or facts context.

Update date

12 Nov 2025

Page type

Company facts

Latest period

Q3 2025

SEC-backed company facts were refreshed from filings filed on 12 Nov 2025.

Open company facts Browse recent public updates

Benchmark Context

Benchmark context for this company

Atai Beckley N.V. has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q3 2025. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 12 Nov 2025.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001840904 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
119
First seen
17 Jun 2021
Latest filing
26 Nov 2025
Entity
Company

Observed form types

10-K 10-Q 10-Q/A 3 3/A 4 4/A SCHEDULE 13D/A

CIK-linked evidence first

Atai Beckley N.V. SEC filings Atai Beckley N.V. 13D/G history Atai Beckley N.V. owner filings Atai Beckley N.V. insider transactions Atai Beckley N.V. company facts Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 119 SEC filings for Atai Beckley N.V..

Open full filing history
4

4 filing

Filing date
26 Nov 2025
Reporting date
25 Nov 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
06 Nov 2025
Reporting date
05 Nov 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
06 Nov 2025
Reporting date
05 Nov 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
29 Oct 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
03 Oct 2025
Reporting date
01 Oct 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
03 Oct 2025
Reporting date
01 Oct 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
02 Oct 2025
Reporting date
30 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Aug 2025
Reporting date
14 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
15 Aug 2025
Reporting date
13 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
14 Aug 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
27 Jun 2025
Reporting date
26 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
27 Jun 2025
Reporting date
26 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .